Doer Biologics Advances Phase 2 Study for Severe Hypertriglyceridemia
Doer Biologics Completes Enrollment in Clinical Study
Zhejiang Doer Biologics Co., Ltd. ('Doer Bio') has successfully completed the enrollment of its Phase 2 clinical study for DR10624, a promising new treatment designed for individuals suffering from severe hypertriglyceridemia (SHTG). This clinical trial marks a significant milestone for Doer Bio as it works towards developing innovative therapies for metabolic diseases.
Details of the DR10624-201 Study
The DR10624-201 study is structured as a randomized, placebo-controlled, double-blind clinical trial focused on evaluating the efficacy and safety of three varying doses of DR10624. Participants in this study are adults diagnosed with SHTG, characterized by elevated fasting triglycerides of 5.65 mmol/L (500 mg/dL) or higher during screening. A total of 79 patients have joined the study, which spans over a period of 12 weeks.
Significance of DR10624
DR10624 is a first-in-class, long-acting tri-agonist that interacts with three key receptors: Fibroblast growth factor 21 receptor (FGF21R), Glucagon receptor (GCGR), and Glucagon-like peptide-1 receptor (GLP-1R). With its innovative development utilizing Doer Bio's proprietary MultipleBody® platform technology, DR10624 has shown immense potential in preclinical and clinical settings, particularly in its ability to significantly reduce triglyceride levels, normalize blood lipids, and enhance liver function.
Insights from Leadership
In discussing the study’s progress, Yanshan Huang, Ph.D., the founder and Chief Executive Officer of Doer Bio, expressed enthusiasm regarding the drug's effectiveness. He highlighted, 'DR10624 was developed with a balanced activity profile that addresses significant metabolic challenges, positioning it as a valuable option for patients.'
Yongliang Fang, Ph.D., the Chief Operating Officer of Doer Bio, elaborated on the public health implications of high triglyceride levels. He noted, 'Patients with SHTG are at a greater risk of severe health complications, including acute pancreatitis and atherosclerotic cardiovascular disease (ASCVD). Our goal with the DR10624-201 study is to find the optimal dose that can pave the way for DR10624 as a novel biologic treatment for these patients.'
Clinical Outcomes and Future Plans
As the trial progresses, the topline results for the DR10624-201 study are anticipated in the third quarter of 2025. This information will be critical in guiding future development and potential availability of DR10624 in treating SHTG.
About Doer Biologics
Doer Biologics is dedicated to addressing unmet medical needs in metabolic diseases and cancer through the discovery and advancement of cutting-edge biotherapeutics. Their innovative approach encompasses various proprietary platform technologies, such as xLONGylation®, MultipleBody®, AccuBody®, and SMART-VHHBody.
Frequently Asked Questions
What is DR10624?
DR10624 is a first-in-class tri-specific agonist developed by Doer Bio targeting specific receptors involved in metabolic diseases.
What is the goal of the DR10624-201 study?
The goal is to evaluate the efficacy and safety of DR10624 in adult patients with severe hypertriglyceridemia.
How many patients are enrolled in the study?
A total of 79 patients have been enrolled in the 12-week clinical study.
What outcomes are expected from the trial?
Topline data regarding the efficacy and safety of DR10624 is expected to be reported in the third quarter of 2025.
What is the significance of metabolic disease treatments?
Treating metabolic diseases such as severe hypertriglyceridemia is crucial in preventing severe complications, including cardiovascular diseases and pancreatitis.
About The Author
Contact Lucas Young privately here. Or send an email with ATTN: Lucas Young as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.